These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 5438434)
41. [Humoral factors in the control of arterial pressure]. Fasciolo JC Medicina (B Aires); 1977; 37 Suppl 1():19-29. PubMed ID: 904467 [No Abstract] [Full Text] [Related]
42. Correlation of pathophysiology and pharmacotherapy in primary hypertension. Koch-Weser J Am J Cardiol; 1973 Sep; 32(4):499-510. PubMed ID: 4593182 [No Abstract] [Full Text] [Related]
43. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma]. Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030 [TBL] [Abstract][Full Text] [Related]
44. Homeostasis and the prostaglandins. Lee JB Trans Stud Coll Physicians Phila; 1973 Jul; 41(1):6-27. PubMed ID: 4354430 [No Abstract] [Full Text] [Related]
45. Mechanisms and quantitative assessment of drug effects on cardiac output with a new model of the circulation. Greenway CV Pharmacol Rev; 1981 Dec; 33(4):213-51. PubMed ID: 7041140 [No Abstract] [Full Text] [Related]
46. The role of vasodilating agents in the treatment of chronic heart failure. Gunnar RM Angiology; 1980 Aug; 31(8):526-32. PubMed ID: 7001960 [No Abstract] [Full Text] [Related]
47. Cardiovascular effects of synthetic physalaemin. Nakano J; Darrow BA; McCurdy JR Arch Int Pharmacodyn Ther; 1968 Apr; 172(2):429-34. PubMed ID: 5684254 [No Abstract] [Full Text] [Related]
48. Pulmonary vascular and renal effects of cromakalim in anaesthetized dogs. Hicks PE; Martin D; Dumez D; Zazzi-Sudriez E; Armstrong JM Pflugers Arch; 1989; 414 Suppl 1():S192-3. PubMed ID: 2780259 [TBL] [Abstract][Full Text] [Related]
49. RA 642, a pyrimido-pyrimidine-derivative with vasodilating and hypertensive potency. Kadatz R; Kobinger W; Walland A Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(2):97-103. PubMed ID: 940597 [TBL] [Abstract][Full Text] [Related]
50. [Changes in rest and exercise hemodynamics during long term therapy with a combination alpha and beta blocker in essential hypertension]. Koch G Verh Dtsch Ges Kreislaufforsch; 1977; 43():219-20. PubMed ID: 349925 [No Abstract] [Full Text] [Related]
51. Systemic and coronary hemodynamic effects of pinacidil in awake normotensive and hypertensive dogs. Kawashima S; Liang CS Hypertension; 1985; 7(4):525-32. PubMed ID: 3891613 [TBL] [Abstract][Full Text] [Related]
52. Pathophysiological rationale for the use of vasodilators in hypertension. Johnston CI Med J Aust; 1975 Jan; 1(SP1):3. PubMed ID: 1124021 [No Abstract] [Full Text] [Related]
53. Peripheral vasodilators in the treatment of cardiac failure. Forrester JS; da Luz PL Adv Cardiol; 1976; 17():123-32. PubMed ID: 818884 [No Abstract] [Full Text] [Related]
54. [Treatment of therapy resistant arterial hypertension with Minoxidil, a peripheral vasodilator agent. Experience of short and long term medication]. Liebau G; Hayduk K Med Welt; 1977 Nov; 28(46):1898-1900. PubMed ID: 413022 [No Abstract] [Full Text] [Related]
55. [Combination of piritramide and N 2 O--a new anesthetic procedure. I. Animal experiment studies]. Kettler D; Braun U; Cott LA; Heiss HW; Hensel I; Martel J; Paschen K; Bretschneider HJ Z Prakt Anasth; 1971 Oct; 6(5):330-8. PubMed ID: 4257163 [No Abstract] [Full Text] [Related]